carvedilol has been researched along with Fatigue in 6 studies
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the UK, the licence for carvedilol was extended in 1998 to include symptomatic heart failure (New York Heart Association [NYHA] class II and III heart failure) with the recommendation that initiation and up-titration should be under the supervision of a hospital physician." | 7.75 | Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. ( Aurich-Barrera, B; Shakir, SA; Wilton, LV, 2009) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 5.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes." | 5.12 | beta-blocker use and diabetes symptom score: results from the GEMINI study. ( Anderson, KM; Bakris, GL; Bell, DS; Dalal, MR; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "In the UK, the licence for carvedilol was extended in 1998 to include symptomatic heart failure (New York Heart Association [NYHA] class II and III heart failure) with the recommendation that initiation and up-titration should be under the supervision of a hospital physician." | 3.75 | Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. ( Aurich-Barrera, B; Shakir, SA; Wilton, LV, 2009) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 1.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aurich-Barrera, B | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Paul, S | 1 |
| Trupp, RJ | 1 |
| Moyer-Knox, D | 1 |
| Mueller, TM | 1 |
| Vuckovic, K | 1 |
| Mischke, L | 1 |
| Williams, RE | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Ekman, I | 1 |
| Cleland, JG | 1 |
| Swedberg, K | 1 |
| Charlesworth, A | 1 |
| Metra, M | 1 |
| Poole-Wilson, PA | 1 |
| McGill, JB | 1 |
| Bakris, GL | 1 |
| Fonseca, V | 1 |
| Raskin, P | 1 |
| Messerli, FH | 1 |
| Phillips, RA | 1 |
| Katholi, RE | 1 |
| Wright, JT | 1 |
| Iyengar, M | 1 |
| Anderson, KM | 1 |
| Lukas, MA | 1 |
| Dalal, MR | 1 |
| Bell, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for carvedilol and Fatigue
| Article | Year |
|---|---|
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
beta-blocker use and diabetes symptom score: results from the GEMINI study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cognition; Diab | 2007 |
3 other studies available for carvedilol and Fatigue
| Article | Year |
|---|---|
Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Dose-R | 2009 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
Remote titration of carvedilol for heart failure patients by advanced practice nurses.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Carbazoles; Carvedilol; Clinical Protocols; Cohort S | 2004 |